Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dabomb Protein BiotechROCO:6578 62 EV-to-EBITDA is 78.93 as of Sep. 10, 2026, which is 582% above its 10-year median of 11.58. GuruFocus rates ROCO:6578 with a GF Score™ of 62/100 and a GF Value™ of NT$17.96 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,661 Consumer Packaged Goods companies, Dabomb Protein Biotech ranks worse than 95.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dabomb Protein Biotech's enterprise value is NT$1,191.1 Mil.
Dabomb Protein Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$15.1 Mil. Therefore, Dabomb Protein Biotech's EV-to-EBITDA for today is 78.93.
The historical rank and industry rank for Dabomb Protein Biotech's EV-to-EBITDA or its related term are showing as below:
ROCO:6578'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -360.71 Med: 11.58 Max: 434.71
Current: 78.93
During the past 13 years, the highest EV-to-EBITDA of Dabomb Protein Biotech was 434.71. The lowest was -360.71. And the median was 11.58.
ROCO:6578's EV-to-EBITDA is ranked worse than 95.24% of 1661
companies
in the Consumer Packaged Goods industry
Industry Median: 9.22
vs ROCO:6578: 78.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Dabomb Protein Biotech (ROCO:6578) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dabomb Protein Biotech's PE Ratio (TTM) for today is calculated as:
Dabomb Protein Biotech's share price for today is NT$17.95.
Dabomb Protein Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Dabomb Protein Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's EV-to-EBITDA falls into.
Dabomb Protein Biotech's current Enterprise Value is NT$1,191.1 Mil.
Dabomb Protein Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$15.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a EV-to-EBITDA of 78.93 as of Sep. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dabomb Protein Biotech. This is 582% above median its historical median of 11.58. According to the industry distribution chart, Dabomb Protein Biotech ranks #1582 out of 1661 companies in the Consumer Packaged Goods industry, placing it in the top 95.2%.
Is Dabomb Protein Biotech's EV-to-EBITDA too high?
Dabomb Protein Biotech's current EV-to-EBITDA of 78.93 is 582% above median its 10-year median of 11.58. The Consumer Packaged Goods industry median EV-to-EBITDA is 9.22. Dabomb Protein Biotech's value of 78.93 is 756.1% above this industry median. Based on the distribution chart, Dabomb Protein Biotech ranks #1582 out of 1661 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Dabomb Protein Biotech has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's EV-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #1582 out of 1661 companies for EV-to-EBITDA. This places Dabomb Protein Biotech in the lower half of its industry. The industry median EV-to-EBITDA is 9.22. Dabomb Protein Biotech's value of 78.93 is 756.1% above this benchmark. While the company's 10-year median is 11.58 vs. the industry median of 9.22, Dabomb Protein Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.22, based on 1,661 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dabomb Protein Biotech's current EV-to-EBITDA of 78.93 is 756.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dabomb Protein Biotech. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current EV-to-EBITDA is 78.93, which is 582% above median its own 10-year median of 11.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Fairly Valued. The stock's GF Value™ is NT$17.96, compared to a current price of NT$17.95 — trading 0.1% below its estimated fair value. The current EV-to-EBITDA is 78.93, which is 582% above median its 10-year median of 11.58 and 756.1% above the Consumer Packaged Goods industry median of 9.22. Dabomb Protein Biotech's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current EV-to-EBITDA is 78.93 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be undervalued.
The current stock price of NT$17.95 is trading 0.1% below its estimated GF Value™ of NT$17.96.
GuruFocus considers Dabomb Protein Biotech to be Fairly Valued.
Key valuation signals for ROCO:6578:
EV-to-EBITDA: 78.93 (582% above median its 10-year median of 11.58)
GF Value™: NT$17.96 vs. price of NT$17.95 (0.1% below fair value)
Industry Position: 756.1% above the Consumer Packaged Goods median (#1582 of 1661)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
62GF Score
Get the complete analysis for ROCO:6578
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
